Navigation Links
Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
Date:5/29/2013

KALAMAZOO, Mich., May 29, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data in a recent issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0062012) on the effects of a new drug for type 2 diabetes in restoring insulin sensitivity and insulin content in human beta- (b-) cells.  Researchers at Washington University in St. Louis, led by Michael McDaniel , PhD, and Nidhi Rohatgi , PhD, found this next generation insulin sensitizer may provide physicians with a new tool for the treatment of diabetes that relieves insulin resistance in human islets, thereby preserving the survival and function of human beta-cells.

Beta-cells are produced in regions in the pancreas referred to as "islets". Their function is to produce, store and release insulin, a hormone essential to the efficient utilization of glucose, a type of sugar that comes from carbohydrate foods and that is the body's main source of energy.[1] In patients with type 2 diabetes, beta-cell death is increased and the number of beta-cells is reduced. In addition, their function may have declined by as much as 80 percent by the time treatment is initiated,[2] resulting in lower insulin levels and higher glucose levels.  In this laboratory study, researchers found that direct treatment of cultured human islets with a new drug for the treatment of type 2 diabetes, MSDC-0160, produced a unique modulation of nutrient sensors that restored normal cell communication mechanisms and enabled the survival and preservation of human beta-cell function, including insulin content.

Diabetes is an undertreated global epidemic affecting an estimated 340 million people worldwide, with a rapidly increasing incidence throughout the developed and developing world. In the United States alone, nearly 26 million adults and children live with the disease. An additional 79 million have pre-diabetes, placing them at increased risk for developing type 2 diabetes. Recently published research by the American Diabetes Association estimates the total costs of diagnosed diabetes have risen to $245 billion in 2012 from $174 billion in 2007, when the cost was last examined. This figure represents a 41 percent increase over a five-year period.

MSDC-0160, a prototype mTOT modulator developed by MSDC, exerts its insulin sensitizing effects through a recently identified mitochondrial protein complex called mTOT™ (mitochondrial target of thiazolidinediones).[3] Data suggest mTOT functions as a molecular sensor switch that coordinates carbohydrate, lipid, and amino acid metabolism with cell function. In addition to preserving beta-cell function as observed in human islets, mTOT modulators have been shown in animal models of type 2 diabetes to improve insulin signaling, decrease calorie-storing "white fat," and increase levels of calorie burning "brown fat."

Recently published Phase 2b clinical data from a study[4] in 258 type 2 diabetic patients further demonstrate modulating mTOT could constitute a new approach for the discovery and development of potentially more useful and novel insulin sensitizers.

About Metabolic Solutions Development Company
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

[1] http://diabetes.webmd.com/blood-glucose.

[2] DeFronzo, RA. Diabetes, Vol. 58, April 2009, pp. 773-795.

[3] http://dx.plos.org/10.1371/journal.pone.0061551: "Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT) - relationship to newly identified mitochondrial pyruvate carrier proteins."

[4] Colca, et al. Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer. Clinical Pharmacology & Therapeutics doi:10.1038/clpt.2013.10 .


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
2. Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
3. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
4. Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation
5. Metabolic Solutions Development Company announces publication of Phase 2b data in Clinical Pharmacology & Therapeutics
6. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
7. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
8. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
9. BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
10. Medifirst Solutions, Inc. Announces Update To Shareholders
11. Life Line Screening and MCM Solutions for Better Health Announce New Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 Spain Glaucoma Surgery Devices Market ... "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Canaloplasty Micro Catheters and Glaucoma Drainage ... distribution shares data for each of these market segements, ...
(Date:12/5/2016)... , Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., ... presented data from two Phase I trials evaluating ... the 58th annual meeting of the American Society ... California . The two datasets show encouraging ... myeloid leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell ...
(Date:12/5/2016)... YORK, Pa. , Dec. 5, 2016  Pennsylvania ... of Drug and Alcohol Programs Gary Tennis ... reversal drug, at Minnich,s Pharmacy in York ... standing order signed by Dr. Levine as a prescription ... "It,s important to remember that any ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... It can ... holiday presents for their four-legged family members as they do for their human friends ... pet parents’ desire to find the highest quality and most innovative pet products has ...
(Date:12/6/2016)... GA (PRWEB) , ... December 06, 2016 , ... ... and the impact of new federal healthcare regulations at the 7th annual Health ... Centre, Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare & ...
(Date:12/6/2016)... ... 2016 , ... The V Foundation for Cancer Research, a ... to Lose fundraising campaign. As the V Foundation’s boldest initiative to date, Not ... The campaign aims to raise $200 million by 2020 and strategically fund emerging, ...
(Date:12/6/2016)... ... 2016 , ... Just in time for the holiday season, the celebrated paleo ... for Honeyville’s new Organic Quinoa Flour product for sale at Costco stores throughout the ... , “I think it’s wonderful that a growing number of retailers such as ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This ... label design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, ...
Breaking Medicine News(10 mins):